In the Phase 1/1b study, sitravatinib was evaluated in patients with metastatic CRPC based on the key roles of MET and VEGFR2 in prostate cancer progression, with high expression levels of both RTKs being associated with aggressive disease [17]. Here, KDR is linked to prostate carcinoma.